Literature DB >> 20963466

Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population.

Zaixing Yang1, Yan Liang, Weiqiang Xi, Chang Li, Renqian Zhong.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by abnormal production of autoantibodies and proinflammatory cytokines. Although interleukin-33 (IL-33), a novel number of the IL-1 family, has been reported to have proinflammatory effects, the association of IL-33 with SLE has remained unknown. The aim of this study was to examine whether the serum IL-33 level is associated with SLE. A total of 70 patients with SLE were recruited. Sera from these patients were obtained at their visit and were compared to sera from 40 healthy controls or 28 patients with rheumatoid arthritis (RA) for IL-33 level. Furthermore, blood samples from patients with SLE were determined for various SLE-related laboratory variables, including blood routine, complements, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and some autoantibodies. Serum IL-33 level was significantly increased in patients with SLE, compared with healthy controls, but was lower than that with RA. In patients with SLE, most clinical and laboratory characteristics did not correlate with serum IL-33 levels, with exceptions of thrombocytopenia, erythrocytopenia, anti-SSB antibody, ESR, CRP and IgA. By Spearman's correlation coefficient, patients with SLE showed close correlation of IL-33 with ESR, CRP and IgA, and by multivariate logistic regressions, patients with SLE showed significantly independent association of IL-33 with thrombocytopenia, erythrocytopenia and anti-SSB antibody. Our results suggest that IL-33 may play a role in acute phase of SLE, but it was not associated with course of the disease. Moreover, IL-33 may exert biologic effects on erythrocytes and platelets or their precursors in SLE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963466     DOI: 10.1007/s10238-010-0115-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  36 in total

Review 1.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors.

Authors:  S Studenski; N B Allen; D S Caldwell; J R Rice; R P Polisson
Journal:  Arthritis Rheum       Date:  1987-12

4.  The increased interleukin-13 in patients with systemic lupus erythematosus: relations to other Th1-, Th2-related cytokines and clinical findings.

Authors:  S Morimoto; Y Tokano; H Kaneko; K Nozawa; H Amano; H Hashimoto
Journal:  Autoimmunity       Date:  2001       Impact factor: 2.815

5.  Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus.

Authors:  Mo Yin Mok; Fang Ping Huang; Wai Ki Ip; Yi Lo; Fung Yi Wong; Eric Yuk Tat Chan; Kwok Fai Lam; Damo Xu
Journal:  Rheumatology (Oxford)       Date:  2009-12-21       Impact factor: 7.580

Review 6.  Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.

Authors:  M Aringer; J S Smolen
Journal:  Lupus       Date:  2004       Impact factor: 2.911

7.  Incidence of systemic lupus erythematosus. Race and gender differences.

Authors:  D J McCarty; S Manzi; T A Medsger; R Ramsey-Goldman; R E LaPorte; C K Kwoh
Journal:  Arthritis Rheum       Date:  1995-09

Review 8.  How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.

Authors:  Virginia Pascual; Florence Allantaz; Pinakeen Patel; A Karolina Palucka; Damien Chaussabel; Jacques Banchereau
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

9.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

Review 10.  The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.

Authors:  Cem Gabay; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more
  31 in total

Review 1.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

2.  Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B.

Authors:  Juan Wang; Yanjun Cai; Huifan Ji; Junyan Feng; Desalegn Admassu Ayana; Junqi Niu; Yanfang Jiang
Journal:  J Interferon Cytokine Res       Date:  2012-02-03       Impact factor: 2.607

Review 3.  Contribution of B-1a cells to systemic lupus erythematosus in the NZM2410 mouse model.

Authors:  Zhiwei Xu; Laurence Morel
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

Review 4.  The deleterious role of basophils in systemic lupus erythematosus.

Authors:  Christophe Pellefigues; Nicolas Charles
Journal:  Curr Opin Immunol       Date:  2013-10-24       Impact factor: 7.486

5.  Severe thrombocytopenia in pregnancy: a case series from west China.

Authors:  Fan Zhou; Tingting Xu; Chunyan Deng; Haiyan Yu; Xiaodong Wang
Journal:  Clin Exp Med       Date:  2019-08-28       Impact factor: 3.984

Review 6.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

7.  Serum IL-33 level and IL-33 gene polymorphisms in Behçet's disease.

Authors:  Suleyman Serdar Koca; Murat Kara; Firat Deniz; Metin Ozgen; Caner Feyzi Demir; Nevin Ilhan; Ahmet Isik
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

8.  IL-33 neutralization suppresses lupus disease in lupus-prone mice.

Authors:  Pin Li; Wei Lin; Xiangxiong Zheng
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

9.  Signal transducer and activator of transcription 5 is implicated in disease activity in adult and juvenile onset systemic lupus erythematosus.

Authors:  Safa Meshaal; Rasha El Refai; Ahmed El Saie; Rabab El Hawary
Journal:  Clin Rheumatol       Date:  2016-04-04       Impact factor: 2.980

10.  Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection.

Authors:  Bruno Cacopardo; Marilia Rita Pinzone; Filippo Palermo; Giuseppe Nunnari
Journal:  Hepat Mon       Date:  2012-12-23       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.